File Download

There are no files associated with this item.

Supplementary

Conference Paper: Targeting AMPK as a valid therapeutic intervention in ovarian cancer

TitleTargeting AMPK as a valid therapeutic intervention in ovarian cancer
Authors
Issue Date2014
Citation
The 2014 International Workshop on Women's Reproductive Health Research, Ottawa, Canada, 11-13 April 2014. How to Cite?
AbstractDespite advances in diagnosis and treatment, the incidence of ovarian cancer is rising and the associated mortality rate has not improved significantly over the past decade. Therefore, discovery of novel targets for therapies will improve the quality of life of patients. AMP-activated protein kinase (AMPK) is an energy-sensor that maintains energy homeostasis in eukaryotic cells. Accumulating evidence has shown that AMPK activation suppresses cell proliferation in response to metabolic stress and induces apoptosis in many human cancer cells. AMPK is a heterotrimer composed of a catalytic subunit (α) and two regulatory subunits (β and γ). Our previous studies found that AMPK subunits are aberrantly expressed in ovarian cancer, and their expressions have significant correlations with ovarian cancer progression (Li et al, 2012). Indeed, we have recently reported that the reduced expression of AMPK-β1 confers lower AMPK activity, which enhances the oncogenic capacity of advanced-stage ovarian cancer (Li, C. et al, 2014, in press).
Persistent Identifierhttp://hdl.handle.net/10722/197740

 

DC FieldValueLanguage
dc.contributor.authorChan, DWen_US
dc.contributor.authorNgan, HYSen_US
dc.date.accessioned2014-05-29T08:46:47Z-
dc.date.available2014-05-29T08:46:47Z-
dc.date.issued2014-
dc.identifier.citationThe 2014 International Workshop on Women's Reproductive Health Research, Ottawa, Canada, 11-13 April 2014.en_US
dc.identifier.urihttp://hdl.handle.net/10722/197740-
dc.description.abstractDespite advances in diagnosis and treatment, the incidence of ovarian cancer is rising and the associated mortality rate has not improved significantly over the past decade. Therefore, discovery of novel targets for therapies will improve the quality of life of patients. AMP-activated protein kinase (AMPK) is an energy-sensor that maintains energy homeostasis in eukaryotic cells. Accumulating evidence has shown that AMPK activation suppresses cell proliferation in response to metabolic stress and induces apoptosis in many human cancer cells. AMPK is a heterotrimer composed of a catalytic subunit (α) and two regulatory subunits (β and γ). Our previous studies found that AMPK subunits are aberrantly expressed in ovarian cancer, and their expressions have significant correlations with ovarian cancer progression (Li et al, 2012). Indeed, we have recently reported that the reduced expression of AMPK-β1 confers lower AMPK activity, which enhances the oncogenic capacity of advanced-stage ovarian cancer (Li, C. et al, 2014, in press).en_US
dc.languageengen_US
dc.relation.ispartofInternational Workshop on Women's Reproductive Health Researchen_US
dc.titleTargeting AMPK as a valid therapeutic intervention in ovarian canceren_US
dc.typeConference_Paperen_US
dc.identifier.emailChan, DW: dwchan@hku.hken_US
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hken_US
dc.identifier.authorityChan, DW=rp00543en_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.identifier.hkuros228889en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats